Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol - ENS de Lyon - École normale supérieure de Lyon Accéder directement au contenu
Article Dans Une Revue Leukemia & lymphoma Année : 2010

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

Résumé

One-third of patients aged ≤60 years with aggressive lymphoma are at low-intermediate risk (LIR). Before the rituximab era, we prospectively compared ACVBP with ECVBP, a similar regimen including epirubicin instead of doxorubicin and increased dose intensity of cyclophosphamide, followed by conventional consolidation with an increased amount and dose intensity of cytosine-arabinoside, methotrexate, etoposide, and ifosfamide, in 652 patients with LIR aggressive lymphoma. The overall response rate, 5-year event-free survival (EFS), and survival were estimated to be 86%, 60%, and 74%, respectively, with no differences between the two arms. In patients with diffuse large B-cell lymphoma (DLBCL) who received ACVBP, the 5-year EFS and survival were estimated at 69% and 82%. These findings do not support the use of a chemotherapy regimen more intensive than ACVBP in patients aged ≤60 years with LIR aggressive lymphoma. The results in the control arm, without rituximab, have led to a randomized comparison of R-ACVBP and R-CHOP in this patient population.

Domaines

Cancer
Fichier non déposé

Dates et versions

ensl-00817207 , version 1 (24-04-2013)

Identifiants

  • HAL Id : ensl-00817207 , version 1

Citer

Pierre Morel, Jean-Nicolas Munck, Bertrand Coiffier, Christian Gisselbrecht, Dana Ranta, et al.. Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. Leukemia & lymphoma, 2010, 51 (9), pp.1668-1677. ⟨ensl-00817207⟩
167 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More